GlassScriptPhysician profile
Zandi W Hudspeth
NPI 1992076434
$3,902.68
in general payments reported to CMS, 2019-2025
25 companies · $873 in 2025
The $873 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $664 · 2022: $812 · 2023: $905 · 2024: $648 · 2025: $873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,426.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $950.52 | 2021-2025 | |
| Novo Nordisk INC | $765.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $502.66 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $341.88 | 2021-2024 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $237.08 | 2021-2025 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $202.40 | 2021-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $150.29 | 2021 | |
| Esperion Therapeutics, INC. | $101.20 | 2021-2024 | Nexletol |
| Boston Scientific Corporation | $92.81 | 2025 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $71.91 | 2022-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $71.75 | 2023-2024 | |
| Pfizer INC. | $51.10 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $47.55 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $45.13 | 2025 | Qelbree |
| Exact Sciences Corporation | $44.16 | 2024-2025 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $34.65 | 2025 | Breztri |
| Lundbeck LLC | $31.70 | 2025 | Rexulti |
| Tris Pharma INC | $31.02 | 2024 | Dyanavel Xr |
| Dexcom, INC. | $24.46 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $23.40 | 2025 | Veozah |
| Renalytix Ai, INC. | $23.08 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Organon LLC | $16.10 | 2023 | Nexplanon |
| Global Blood Therapeutics, INC. | $15.15 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.53 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.49 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zandi Hudspeth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.